GLP-1-based therapies are proposed as a potential treatment for resistant hypertension in overweight or obese individuals, though no direct trials currently exist.
Does GLP-1-based therapy improve blood pressure control in individuals with resistant hypertension who are overweight or obese?
This review highlights the potential of GLP-1-based therapies for managing resistant hypertension in overweight or obese patients, identifying a critical gap in direct clinical trial evidence.
Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control. Obesity ranks among the most significant modifiable risk factors for RHTN, with 56-91% of patients with RHTN classified as overweight or obese. Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) are a class of anti-obesity medications that have recently demonstrated efficacy in reducing BP and improving cardiovascular (CV) outcomes in individuals with overweight or obesity. Among the available GLP-1-based therapies, liraglutide, semaglutide, and tirzepatide have been approved for chronic weight management in this population. Tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has the greatest effect on weight loss and BP reduction compared to GLP-1 RAs alone. To our knowledge, no trials have directly evaluated the effect of GLP-1 RAs or dual GLP-1/GIP receptor agonists on RHTN management. In this review article, we propose that targeting weight loss through GLP-1-based therapies should be explored as a treatment option for individuals with RHTN who are overweight or obese.
Jarade et al. (Thu,) conducted a review in Resistant hypertension in individuals with overweight or obesity. GLP-1-based therapies was evaluated. GLP-1-based therapies are proposed as a potential treatment for resistant hypertension in overweight or obese individuals, though no direct trials currently exist.